About the job
Revolution Medicines is a pioneering clinical-stage precision oncology firm dedicated to advancing innovative targeted therapies that effectively inhibit cutting-edge targets in RAS-addicted cancers. Our robust R&D pipeline features RAS(ON) Inhibitors engineered to suppress various oncogenic variants of RAS proteins, alongside RAS Companion Inhibitors designed for synergistic treatment strategies. By joining our dynamic team, you will become part of a passionate group committed to making a meaningful difference for patients battling cancers driven by mutations in the RAS signaling pathway.
The Opportunity:
As the Executive Director and Head of Japan Medical Affairs, reporting directly to the President and Representative Director Japan, you will spearhead the formulation and implementation of Revolution Medicines' Medical Affairs strategy within Japan. This pivotal leadership position is essential for maximizing the potential of RevMed Innovation to positively impact patients in Japan. Collaborating closely with the President and Representative Director Japan as well as the SVP Head of Global Medical Affairs, you will be responsible for devising and executing comprehensive medical strategies to foster engagement with key stakeholders in Japan, including government bodies, regulatory authorities, payers, and healthcare professionals. As an integral member of the Japan Leadership Team, you will work across various functions to establish and execute the strategic vision for Japan.
In this role, you will ensure that the medical perspectives of Japan are fully integrated into the broader global medical strategy and plans. You will collaborate with the VP Head of Japan and market access teams to guarantee that reimbursement and access considerations are incorporated into the design of both current and future clinical programs within the company's portfolio. Additionally, you will be tasked with building and leading the Japan medical affairs team, working closely with various Med Affairs functions, including Medical Information, Pharmacovigilance, and Health Economics and Outcomes Research (HEOR).

